The name of the guest speaker at Emoryâ€™s Office of Technology Transferâ€™s annual celebration on March 7 provoked some double takes around campus last week.
Todd B. Sherer, PhD, CEO of the Michael J. Fox Foundation for Parkinsonâ€™s Research (MJFF), described how the Fox Foundation is trying to build bridges between the worlds of basic and clinical research to speed development of new drugs for the treatment of Parkinsonâ€™s disease, and offered a ray ban outlet perspective on how independent research funders can help move drug candidates from the lab to the clinic and closer to market.
Sherer, a former postdoctoral fellow at Emory, also has the same first and last name (but not middle initial!) as OTTâ€™s director. Sherer â€“ the one who works for the Fox Foundation â€“ joined that non-profit charityâ€™s staff in 2004. While at Emory, he worked on models for Parkinsonâ€™s based on exposure to the pesticide rotenone, alongside Ranjita Betarbet, Gary Miller and J. Timothy Greenamyre, who himself moved on to the University of Pittsburgh in 2005.